Combined-modality therapy for gastric cancer

2003 ◽  
Vol 21 (4) ◽  
pp. 223-227 ◽  
Author(s):  
James C. Yao ◽  
Paul F. Mansfield ◽  
Peter W.T. Pisters ◽  
Barry W. Feig ◽  
Nora A. Janjan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

Combined Modality Therapy of Gastric Cancer

1997 ◽  
Vol 6 (4) ◽  
pp. 741-747 ◽  
Author(s):  
Martin S. Karpeh ◽  
David P. Kelsen
Keyword(s):  
Gastric Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response

2006 ◽  
Vol 24 (24) ◽  
pp. 3953-3958 ◽  
Author(s):  
Jaffer A. Ajani ◽  
Kathryn Winter ◽  
Gordon S. Okawara ◽  
John H. Donohue ◽  
Peter W.T. Pisters ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Adenocarcinoma ◽  
Combined Modality Therapy ◽  
Preoperative Chemoradiotherapy ◽  
Cooperative Group ◽  
Group Setting ◽  
End Points ◽  
D2 Dissection ◽  
Combined Modality

Purpose Preoperative therapy for localized gastric cancer has considerable appeal. We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points. Patients and Methods Patients with localized gastric adenocarcinoma were eligible. A negative laparoscopic evaluation was required. Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel). Resection was attempted 5 to 6 weeks after chemoradiotherapy was completed. Quality of therapy was assessed with other end points. Results Twenty institutions participated. Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage III). The pathCR and R0 resection rates were 26% and 77%, respectively. At 1 year, more patients with pathCR (82%) are living than those with less than pathCR (69%). Grade 4 toxicity occurred in 21% of patients. Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98%, 44%, and 63% of patients, respectively. A D2 dissection was performed in 50% of patients. Of 18 major radiotherapy variations, 17 were due to the lack of inclusion of the L3-4 vertebral interphase as prespecified. Conclusion For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting. The quality of surgery improved (50% with D2 dissection) possibly because surgery was part of this trial. With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.

scholarly journals Resection of the Gastric Tube Reconstructed through the Retrosternal Route without Sternotomy

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Masahiro Kimura ◽  
Yasuyuki Shibata ◽  
Kotaro Mizuno ◽  
Hironori Tanaka ◽  
Motoki Hato ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Gastric Tube ◽  
Early Stage ◽  
Combined Modality Therapy ◽  
First Report ◽  
Gastric Tube Cancer ◽  
Subtotal Esophagectomy ◽  
Combined Modality ◽  
Advanced Stages

With advances of combined modality therapy, prognoses in esophageal cancer have been improving. After resection of esophageal cancer, the development of gastric tube cancer is a risk. While such cancer in an early stage can be cured endoscopically, total gastric tube resection is indicated in advanced stages. A 68-year-old man underwent subtotal esophagectomy reconstructed with a gastric tube through the retrosternal route. Gastric cancer was found one and a half years postoperatively. The gastric tube was resected without sternotomy. This is the first report of a patient undergoing resection of the gastric tube reconstructed through the retrosternal route without sternotomy.

Evolving trends in combined modality therapy for pancreatic cancer

1998 ◽  
Vol 5 (3) ◽  
pp. 227-234 ◽  
Author(s):  
William F. Regine ◽  
William J. John ◽  
Mohammed Mohiuddin
Keyword(s):  
Pancreatic Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

scholarly journals Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Dacia S. K. Boyce ◽  
John W. Lee ◽  
Phalgoon Shah ◽  
Judy H. Freeman ◽  
Matthew C. Aboudara ◽  
...  
Keyword(s):  
Case Report ◽  
Pulmonary Alveolar Proteinosis ◽  
Combined Modality Therapy ◽  
Combined Modality ◽  
Alveolar Proteinosis ◽  
Remote Setting
Sign in / Sign up

Export Citation Format

Share Document